Octagon Therapeutics

Octagon Therapeutics

Octagon Therapeutics

The Pew Trusts estimates that, by 2050, resistant infections will be responsible for more deaths than cancer. Octagon is developing a vitally important new class of antibiotics to address these bacterial threats.
Founded
2017
Follow us
Alexa global traffic share
Twitter followers
Latest funding
Undisclosed amount
Seed fund - 2018
MassChallenge
Team Size
2
Employees
FinSMEs

Octagon Therapeutics Closes Financing Round

Health Funding Science